Coronary Artery Bypass Graft Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Coronary artery bypass graft surgery (CABG, commonly pronounced 'cabbage') is an open-heart surgical procedure that creates new routes for blood to reach the heart muscle by bypassing narrowed or blocked coronary arteries. It is one of the most commonly performed major cardiac operations worldwide, with approximately 200,000 procedures performed annually in the United States alone, and represents the standard of care for selected patients with severe multivessel coronary artery disease, left main coronary artery disease, and coronary anatomy not suitable for percutaneous coronary intervention (PCI).

In coronary artery disease, atherosclerotic plaques progressively narrow the lumen of the coronary arteries, reducing blood supply to the myocardium and causing angina, reduced exercise tolerance, and, with acute plaque rupture, myocardial infarction. CABG does not remove the existing blockages; instead, it creates new conduits — grafts harvested from arteries or veins elsewhere in the body — that are sewn onto the coronary arteries beyond the blockages, restoring adequate myocardial blood flow.

The left internal mammary artery (LIMA, also called the internal thoracic artery) is the most important and durable conduit. It is left attached to its origin at the subclavian artery, mobilised from the chest wall, and sewn onto the left anterior descending (LAD) artery — the most important coronary artery supplying the anterior left ventricle. The LIMA-to-LAD graft has a patency (open) rate of greater than 90% at 10 years and greater than 80% at 20 years, dramatically superior to saphenous vein grafts, which have a 10-year patency of approximately 50–60%. Bilateral LIMA grafting (also using the right IMA), total arterial revascularisation with radial artery grafts, and off-pump CABG (performed on the beating heart without cardiopulmonary bypass) are important surgical refinements.

CABG is primarily indicated for severe coronary artery disease causing medically refractory angina or documented extensive myocardial ischaemia. Left main coronary artery stenosis (>50% or ≥70% with FFR ≤0.80) is the most classic CABG indication, as the left main supplies the majority of the left ventricular myocardium and severe stenosis here causes massive ischaemia with catastrophic consequences if the artery acutely occludes. Three-vessel disease (significant stenosis in all three major coronary arteries: LAD, circumflex, right coronary) with a high SYNTAX score (>22) is a primary CABG indication, particularly in patients with diabetes where CABG is superior to PCI for multivessel disease.

CABG combined with other cardiac surgery — mitral valve repair/replacement for ischaemic mitral regurgitation, left ventricular reconstruction (Dor procedure) for post-infarct left ventricular aneurysm, or aortic valve replacement for concomitant severe aortic stenosis — addresses multiple pathologies in a single operation. Emergency or urgent CABG may be required for failed PCI with ongoing ischaemia, acute myocardial infarction with cardiogenic shock where the coronary anatomy is unsuitable for PCI, or left main occlusion with haemodynamic compromise. Reoperative CABG (redo surgery) for late graft failure requires highly specialised surgical expertise and carries higher operative risk than primary CABG.

The Heart Team — comprising an interventional cardiologist, cardiac surgeon, imaging specialist, and anaesthetist — evaluates each patient collaboratively for revascularisation strategy. The SYNTAX score derived from coronary angiography classifies anatomical complexity and guides the PCI-versus-CABG decision. High SYNTAX scores (>33) and multivessel disease with diabetes strongly favour CABG, as demonstrated in the SYNTAX, FREEDOM, and EXCEL trials. Formal Heart Team assessment is a Class I recommendation in ESC/ACC/AHA guidelines.

Left ventricular function (ejection fraction) and overall cardiac risk are assessed using echocardiography and the European System for Cardiac Operative Risk Evaluation (EuroSCORE II) or Society of Thoracic Surgeons (STS) risk calculator. Expected surgical mortality for elective isolated CABG is 1–2% at experienced centres in low-risk patients, rising with age, impaired LV function, CKD, prior cardiac surgery, and emergency setting. Patients must be able to tolerate general anaesthesia, sternotomy (chest opening), and a recovery period of 6–12 weeks. Severe peripheral vascular disease may limit conduit availability; patients with poor lung function require pre-operative respiratory optimisation. Frailty assessment is increasingly incorporated into the decision for elderly patients.

Conventional on-pump CABG is performed through a median sternotomy (vertical incision along the breastbone) with cardiopulmonary bypass (heart-lung machine) support. The heart is stopped with cardioplegic solution and cooled, allowing the surgeon to work on a still, bloodless field. The LIMA is mobilised and anastomosed (sewn) to the LAD; saphenous vein grafts (SVGs) harvested from the leg (via open or endoscopic harvest) are sewn from the aorta to other bypassed vessels. The heart is restarted and the patient is weaned from bypass. This technique provides optimal visualisation and allows complex reconstructions.

Off-pump CABG (OPCAB) is performed on the beating heart without cardiopulmonary bypass, using a mechanical stabiliser device that immobilises a small section of the beating heart at the anastomotic site. Proponents cite reduced stroke, neurological complications, and renal injury by avoiding CPB. The landmark CORONARY and ROOBY trials showed no significant long-term mortality advantage but lower early stroke rates; OPCAB requires specialised surgical expertise and is performed at high-volume centres. Minimally invasive CABG approaches include MIDCAB (minimally invasive direct coronary artery bypass) for isolated LAD disease via a small anterolateral thoracotomy without sternotomy, and robotic-assisted CABG at highly specialised centres. Bilateral internal mammary artery (BIMA) grafting uses both LIMA and RIMA as conduits, improving long-term graft patency and survival versus single IMA grafting, particularly in younger patients, at the cost of a slightly increased risk of sternal wound infection in diabetic patients.

CABG provides superior long-term outcomes compared to PCI in defined patient groups. In the SYNTAX trial, 5-year follow-up showed significantly lower rates of repeat revascularisation (13.7% vs 25.9%) and major adverse cardiac and cerebrovascular events in patients with three-vessel disease and left main disease treated with CABG versus PCI. For patients with diabetes and multivessel disease, the FREEDOM trial demonstrated a significant survival advantage with CABG over PCI at 5 years (all-cause mortality 10.9% CABG vs 16.0% PCI).

CABG achieves complete revascularisation — treating all significant lesions — more reliably than PCI in diffuse multivessel disease, with superior long-term freedom from angina and repeat procedures. The LIMA graft to the LAD is virtually a 'permanent' conduit with 20-year patency exceeding 80%, while saphenous vein grafts offer 50–60% patency at 10 years. In the STICH trial, CABG with optimal medical therapy improved 10-year survival compared to medical therapy alone in patients with LV dysfunction (EF ≤35%) and CAD, establishing the survival benefit of surgical revascularisation in heart failure patients with viable myocardium.

Stroke is the most feared neurological complication, occurring in approximately 1–2% of elective CABG, related to embolism from the aortic cannulation site and manipulation of the calcified aorta. Neurocognitive dysfunction (termed 'pump head' — memory impairment, attention difficulties) is reported in up to 30–40% of patients in the early post-operative period, largely resolving by 3–6 months. Atrial fibrillation (AF) is the most common post-operative complication, occurring in 25–40% of patients, typically on post-operative days 2–4, managed with rate control and anticoagulation.

Sternal wound complications, including superficial wound dehiscence and deep sternal wound infection (mediastinitis), occur in 1–2% of patients. Bilateral IMA harvesting and diabetes are risk factors for sternal wound infection; vacuum-assisted closure (VAC) and pectoralis muscle flap reconstruction are the treatments. Saphenous vein graft failure is an ongoing concern: approximately 10–15% of SVGs occlude in the first year, and only 50–60% are patent at 10 years, driving repeat presentations with angina and the need for re-intervention. Chronic kidney disease deterioration, bleeding requiring re-exploration, and prolonged mechanical ventilation are other important complications that the surgical team monitors closely in the intensive care unit.

After CABG, patients typically spend 1–2 days in the cardiac surgical intensive care unit (CICU) for monitoring and optimisation of cardiac function, fluid balance, and respiratory support. Total hospitalisation is 5–8 days. A phased recovery programme begins in hospital: physiotherapists guide breathing exercises and progressive mobilisation from post-operative day 1. Chest tubes and pacing wires are removed by day 3–5, and urinary catheters and arterial lines are removed as the patient stabilises.

Cardiac rehabilitation is strongly recommended and evidence-based for CABG patients — a structured 8–12 week supervised exercise and lifestyle programme reduces all-cause mortality by 20–25% and hospital readmission by 30% (Cochrane review). Full sternal healing requires 6–8 weeks, during which patients must avoid lifting more than 5 kg, driving, and vigorous arm movements. Return to office work is typically 6–8 weeks; physical labour requires 10–12 weeks. Mandatory medications include aspirin 75–100 mg indefinitely, high-intensity statin, ACE inhibitor or ARB, and beta-blocker. Low-dose aspirin combined with ticagrelor for the first year after CABG (if no high bleeding risk) improves SVG patency. Annual follow-up with a cardiologist assesses symptoms, functional status, and SVG patency monitoring by CT coronary angiography or nuclear stress testing.

CABG is a major surgical procedure with correspondingly high costs in Western healthcare systems. In the United States, isolated elective CABG costs USD 70,000–150,000, including surgical fees, anaesthesia, ICU care, hospitalisation, and cardiac rehabilitation. Complex CABG with concurrent valve surgery can exceed USD 200,000. In the UK, NHS CABG is provided free; private costs are GBP 15,000–30,000 at specialised cardiac centres.

Coronary bypass surgery at high-volume cardiac centres in India — Narayana Health (Bangalore, founded by Dr Devi Shetty), Fortis Escorts Heart Institute (New Delhi), Apollo Hospitals, and Kokilaben Dhirubhai Ambani Hospital (Mumbai) — costs USD 5,000–10,000 all-inclusive for isolated CABG, representing 85–90% savings versus US pricing. These centres perform extraordinary surgical volumes: Narayana Health's Bangalore facility performs over 3,000 open-heart surgeries per year. Internationally trained cardiothoracic surgeons trained at Mayo Clinic, Cleveland Clinic, and UK cardiac surgery units staff these centres. Published outcomes data for CABG in major Indian cardiac centres shows 30-day mortality of 1–2% for isolated CABG, comparable to US and European centres. Thailand (Bangkok Heart Hospital, Bumrungrad) costs USD 12,000–20,000. Turkey (Acıbadem, Florence Nightingale) costs USD 10,000–18,000.

Percutaneous coronary intervention (PCI) with drug-eluting stenting is the primary catheter-based alternative to CABG, appropriate for patients with lower SYNTAX scores, single-vessel disease, left main disease without complex anatomy (SYNTAX ≤22), or high surgical risk making CABG hazardous. The choice between CABG and PCI is not absolute — it requires Heart Team evaluation of coronary anatomy, patient preferences, comorbidities, and the local surgical and interventional expertise available.

Optimal medical therapy (OMT) — maximally tolerated antiplatelet therapy, high-intensity statins, beta-blockers, ACE inhibitors, and nitrates — improves symptoms and prognosis in CAD, and the ISCHEMIA trial showed no mortality benefit from revascularisation (whether PCI or CABG) over OMT alone in stable patients with moderate-to-severe ischaemia at a median 3-year follow-up. This has reinforced OMT as a valid strategy for stable patients, with revascularisation reserved for those with refractory symptoms or high-risk anatomy (left main, proximal LAD disease). Transmyocardial laser revascularisation (TMR) is a surgical technique creating channels in the myocardium to promote angiogenesis, used only as an adjunct at the time of CABG or as a standalone procedure for patients with refractory angina and no option for PCI or CABG. Cardiac rehabilitation alone, without revascularisation, provides meaningful functional improvement and quality-of-life benefit in patients ineligible for invasive procedures.